Radiopharmaceuticals (Strontium 89) and radiosensitizers (idoxuridine).

Article Details

Citation
Copy to clipboard

Otto SE

Radiopharmaceuticals (Strontium 89) and radiosensitizers (idoxuridine).

J Intraven Nurs. 1998 Nov-Dec;21(6):335-7.

PubMed ID
10392098 [ View in PubMed
]
Abstract

Strontium 89, a radiopharmaceutical, has proved effective in treating pain associated with multiple osteoblastic bony metastasis from prostate or breast cancer. The drug is given intravenously in an outpatient setting. Pain relief may be noted within 1 to 2 weeks and may last for several weeks or months. Radiosensitizers such as idoxuridine incorporate into the DNA and increase the susceptibility of the cancer cell to radiation damage. Hypoxic cell sensitizers (such as metronidazole, misonidazole, SR 2508, and Ro-038799) increase oxygen to the cancer hypoxic cells and promote damage of the DNA, thus preventing cell repair.

DrugBank Data that Cites this Article

Drugs